Our CSO, Dr. Giordano, sat down with EricDye to discuss JanOne, the treatment of PAD, bringing to market drugs with non-addictive pain-relieving properties, and more.
JanOne Successfully Begins Production of #JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (#PAD) Trial and… https://t.co/lyQb1LhYSc
JanOne (Nasdaq: JAN) Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease.
When treating PAD associated pain, 25% of patients are at risk for opioid prescriptions. If we treat PAD at the source, we remove the need for pain-relieving medications. Learn more here: https:// janone.com/ why-we-exist/
JanOne Announces Strategic Plan to Divest its Legacy Businesses.
Our first drug candidate is being tested to treat #PAD. We have assembled an amazing team of experts in vascular… https://t.co/ayBq7eUNt3
It's #PADAwareness Month. Click the link to learn more about Peripheral Artery Disease, the signs and symptoms and… https://t.co/zsF1F9K99d
Thank you, @OutsourcPharma, for featuring our latest news about our developmental batch of JAN101, aimed to potenti… https://t.co/yZ0bsFQA2t
JanOne Inc to ramp up production of its lead therapy JAN101 as a potential #coronavirus treatment via @proactive_NA… https://t.co/2y0EFk87v7
Our CSO will at the LD 500 today at 3 PM ET to discuss upcoming developments, an overview of our drug candidate JAN… https://t.co/f1P0rtNY3o